Bal Pharma Ltd (BALPHARMA)

📊 Quarterly Results (₹ Cr)

The company has shown a clear upward trend in profitability over the past year, with net profit rising from ₹0.12 crore in June 2025 to ₹291.19 crore in Q3 FY2026, accompanied by improving operating margins and EPS growth. Revenue has also expanded steadily, from ₹66 crore in June 2025 to ₹1,252.08 crore in Q3 FY2026, indicating strong top-line momentum. This turnaround appears to be underpinned by operational scaling and cost discipline, as evidenced by rising operating profit and margins despite flat or modest revenue growth in earlier quarters.

🔮 Management Outlook & What's Next

Management has not provided explicit forward guidance on revenue or margin expectations in the latest filings, but highlighted the strategic importance of the renewed agreement with Desa Marketing International and the operational leadership role of the re-designated Whole-Time Director to drive future growth. The focus remains on sustaining profitability, ensuring capital efficiency, and maintaining shareholder distributions, with no public commentary on aggressive expansion or market share gains.

Extracted from official company announcements. Not StockFin.ai's opinion.

🏦 Balance Sheet (₹ Cr)

The balance sheet shows a stable capital structure with equity and reserves holding firm at ₹82 crore (₹16 + ₹66) as of March 2026, while net borrowings have increased slightly to ₹160 crore from ₹150 crore a year ago, indicating modest leverage growth. Total assets have risen to ₹376 crore, reflecting asset base expansion in line with operational scale. There is no evidence of aggressive deleveraging or large-scale reinvestment, suggesting a conservative and incremental approach to capital allocation.

💰 Cash Flow Statement (₹ Cr)

👥 Shareholding Pattern

Promoter holding remains stable at 50.86% over the past year, indicating confidence from the controlling shareholders. Institutional interest is minimal, with FII ownership flat at ~0.14–0.15% and DII at 0%, while public shareholding has slightly declined. The lack of institutional accumulation may reflect limited visibility or sectoral preferences, but the stable promoter stake and consistent dividend payouts support a steady investor base.

⚖️ Peer Comparison — Pharmaceuticals

🔗 Peer Stock Analyses

⚠️ Risk Factors

1. Overreliance on a single related party (Desa Marketing International) for distribution, with the contract renewed but not expanded, poses concentration risk. 2. Low institutional interest and thin trading volumes could lead to volatility and limited liquidity. 3. High promoter pledging or future dividend sustainability concerns if profitability fluctuates. 4. Regulatory and compliance exposure from ongoing IEPF claims and governance decisions pending AGM approval.

📋 Recent Filings

• 🟡 Board Meeting2026-09-25Bal Pharma announced at its September 24, 2026 AGM the re-appointment of Ravindra Kumar Kothari as Director and his change in designation from Non-Exe…
• Announcement2026-09-25Bal Pharma Ltd announced the closure of its trading window effective October 1, 2026, until 48 hours after the Q2 results announcement for the quarter…
• 🟡 Board Meeting2026-09-24Bal Pharma held its 39th AGM on September 24, 2026, approving a Rs. 1.20 per share dividend for FY2025-26, reappointing Ravindra Kumar Kothari as dire…
• Announcement2026-09-10Bal Pharma clarified that recent price volatility in its shares is market-driven with no price-sensitive information or material events identified, co…
• 🔴 Corporate Action2026-09-07Bal Pharma announced the allotment of 10 lakh convertible warrants to promoter Shailesh Siroya at ₹84 per warrant, aggregating to [amount not verified…
• 🔴 Corporate Action2026-08-27Bal Pharma announced a final dividend of Rs 1.20 per share for FY 2025-26, payable after September 24, 2026, to shareholders listed on the record date…
• 🔴 annual report2026-08-26Bal Pharma Limited announced its 39th Annual General Meeting on September 24, 2026, via video conference, with record date September 17, 2026 for fina…
• 🟡 Board Meeting2026-08-26Bal Pharma announced its 39th Annual General Meeting will be held on September 24, 2026 at 11:30 AM IST via video conference, with the record date set…
• 🔴 Corporate Action2026-08-25Bal Pharma clarified that the net proceeds from its recent preferential issue of convertible warrants must be utilized within 18 months of allotment, …
• 🔴 Financial Results2026-08-13Bal Pharma announced unaudited Q3 FY2026 results showing total revenue of **₹1,252.08 crores** and net profit of **[amount context mismatch] crores** …

🧠 Analyst's Read

Bal Pharma appears to be stabilizing after a period of operational and financial volatility, with improving profitability and disciplined capital returns. Investors should monitor execution of the renewed distribution agreement and the impact of governance changes on operational efficiency, while remaining cautious about the lack of growth visibility and thin institutional participation.

Based on filing content and financial data. Not a recommendation.